Li Nandi, Tan Qian, Jing Wei, Luo Ping, Tu Jiancheng
Department of Clinical Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, China.
Pathol Oncol Res. 2017 Oct;23(4):731-736. doi: 10.1007/s12253-016-0182-2. Epub 2017 Jan 4.
Emerging evidences suggested that long non-coding RNAs (lncRNAs) play an interesting role in the tumor development and progression in various types of cancer. The aim of this study was to analyse the potential prognostic value for cancer patients . We systematically searched the reports through PubMed, Web of Science, Medline, CNKI, and the Cochrane Library from inception to March, 2016, and carefully identified according to eligibility criteria. This quantitative meta-analysis collected all relevant articles to investigated the association of SPRY4-IT1 expression status with overall survival (OS) and lymph node metastasis (LNM). A total of 765 patients with cancer from 8 studies were included in the final analysis. The hazard ratio (HR) of OS and the odds ratios (OR) of LNM were calculated to assess the association . The meta-analysis results showed high SPRY4-IT1 expression could predict unfavorable OS in various cancers (pooled HR: 2.18, 95% CI: 1.45-3.27, p = 0.001). Moreover, we found high SPRY4-IT1 expression was related to LNM (pooled OR = 3.86, 95%CI:1.31-11.35, P = 0.01). LncRNA SPRY4-IT1 can serve as a new molecular marker for cancer metastasis and prognosis.
新出现的证据表明，长链非编码RNA（lncRNAs）在各类癌症的肿瘤发生和发展过程中发挥着重要作用。本研究旨在分析其对癌症患者的潜在预后价值。我们通过PubMed、Web of Science、Medline、中国知网和Cochrane图书馆系统检索了从创刊至2016年3月的相关报告，并根据纳入标准进行了仔细筛选。这项定量荟萃分析收集了所有相关文章，以研究SPRY4-IT1表达状态与总生存期（OS）和淋巴结转移（LNM）之间的关联。最终分析纳入了来自8项研究的765例癌症患者。计算OS的风险比（HR）和LNM的比值比（OR）以评估两者之间的关联。荟萃分析结果显示，SPRY4-IT1高表达可预测多种癌症患者的不良OS（合并HR：2.18，95%CI：1.45 - 3.27，p = 0.001）。此外，我们发现SPRY4-IT1高表达与LNM相关（合并OR = 3.86，95%CI：1.31 - 11.35，P = 0.01）。LncRNA SPRY4-IT1可作为癌症转移和预后的新型分子标志物。
